What it is
GLOW is a pre-formulated research peptide blend combining three compounds in a single lyophilized vial: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex, 50 mg), BPC-157 (body protection compound, a 15-amino-acid synthetic pentadecapeptide, 10 mg), and TB-500 (a synthetic fragment of thymosin beta-4, 10 mg). The formulation totals 70 mg and is standardized at a 5:1:1 ratio across most research vendors.
Each component has its own published research literature. GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma. BPC-157 was originally isolated from human gastric juice. TB-500 is a synthetic analog of the actin-binding region of thymosin beta-4, an endogenous protein involved in cell migration and repair. The blend is sometimes marketed under the GLOW trade name, but the formulation is not proprietary to any single vendor.
What researchers study it for
- Skin collagen synthesis and dermal remodeling In vitro studies have shown that GHK-Cu increases collagen and glycosaminoglycan synthesis in fibroblast cultures, and gene expression analyses suggest it may influence pathways associated with extracellular matrix production.[1][2]
- Wound healing and tissue repair Thymosin beta-4 (the source peptide for TB-500) has been examined in preclinical wound models and in two Phase 2 clinical trials of stasis and pressure ulcers, where it was observed to reduce healing time by approximately one month in patients who did heal.[5]
- Angiogenesis and vascular support Thymosin beta-4 promotes cell migration, VEGF signaling, and stem cell mobilization in preclinical models, with proposed applications in ischemic tissue repair and wound vascularization.[6]
- Tendon, ligament, and musculoskeletal repair BPC-157 has been studied extensively in rodent models of tendon transection and ligament injury, where it appears to activate VEGFR2 and nitric oxide signaling pathways associated with fibroblast activity and angiogenesis.[3]
- Anti-inflammatory activity and tissue protection Preclinical reviews note that BPC-157 reduces inflammatory cytokine activity and improves microvascular integrity across multiple animal model systems, though human clinical data remains limited.[4]
- Gene expression and antioxidant pathways Gene profiling analyses of GHK-Cu suggest it may upregulate pathways associated with antioxidant defense and DNA repair while downregulating pro-fibrotic and inflammatory gene sets, though functional confirmation in human tissue is still being investigated.[2]
Research context
The GLOW blend itself has not been evaluated as a combined formulation in published clinical trials. The available evidence base covers each component individually, and the three peptides have meaningfully different research profiles. GHK-Cu has a substantial in vitro literature focused on fibroblast behavior and collagen synthesis, along with topical human data from cosmetic dermatology. The systemic (injected) evidence for GHK-Cu in humans is more limited.[1] BPC-157 has a large body of rodent studies (well over 100 published papers) examining gut mucosal repair, tendon healing, and inflammation, but as of 2026 no large-scale human RCTs have been completed.[3]
TB-500 sits in between: thymosin beta-4 has progressed to Phase 2 clinical trials for chronic wound applications, giving it more human data than BPC-157 but still well short of an approved therapy.[5] Researchers studying the GLOW blend are essentially working with three preclinical-stage compounds whose mechanisms overlap in tissue repair, collagen signaling, and angiogenesis. The blend format is convenient for research protocols that want to study all three simultaneously, but the combined effect has not been characterized in published literature.
Typical research parameters
| Parameter | Typical range |
|---|---|
| Common vial sizes | 70 mg (50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500) |
| Supplied as | Lyophilized powder blend; reconstituted with bacteriostatic water prior to use |
| Storage | Lyophilized powder stored protected from light; refrigerate after reconstitution |
| Stability | Lyophilized: 24+ months at room temperature / Reconstituted: 4–6 weeks refrigerated |
| Administration studied | Subcutaneous injection (as studied for each component individually in preclinical literature; topical also studied for GHK-Cu) |
References
- [1] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. PubMed ↗
- [2] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. PubMed ↗
- [3] McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611–619. PubMed ↗
- [4] From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International Journal of Molecular Sciences. 2026;27(6):2876. PubMed ↗
- [5] Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences. 2012;1270:37–44. PubMed ↗
- [6] Smart N, et al. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. 2007;10(4):229–241. PubMed ↗